TNA1: BPRC will provide access to its P. pastoris systems, which allow the constitutive or inducible expression of intracellular or secreted proteins. BPRC will also provide P. pastoris strains overexpressing chaperone/helper proteins to boost expression levels. TNA3: BPRC will offer access to its library of human cell reporter assays for the identification of innate immune receptor-induced signalling cascades, including human cell lines transfected with PAMPs such as TLR and/or engineered to express luciferase in response to NF-kB or IFRE-mediated signal transduction, and cell lines that provide insight into the intracellular signalling cascades of innate immune receptors. These lines allow for qualitative and quantitative assessment of innate immune responses provoked by different stimuli, resulting in innate immune response fingerprints. TNA8: BPRC will provide access to macaques for immunogenicity/adjuvanticity evaluation of vaccine candidates for malaria, tuberculosis, HIV, influenza, West Nile virus or dengue virus, with up to three (prime-boost) immunisation events. The service includes baseline assessments and post-vaccination follow-up by biosample collection, as well as standard and/or user specific humoral and/or cellular immunology tests. Additional study objectives, such as challenge or advanced immunological assessments or imaging, may be discussed. NA3: BPRC will provide a five-day module on Statistics of vaccine evaluation. It will address statistical and methodological topics for the pre-clinical and clinical evaluation of vaccines and includes lectures followed by hands-on training.